COVID-19 is no longer a threat to clinical trials; now the concern of biotechnology is how to manage their own trials during the crisis. A joint survey by BioCentury and BIO finds that protocol changes are needed quickly, and companies want certification controllers to be flexible with the resulting data sets.
